DK0552624T3 - Anvendelse af 9-cis-retinsyre, salte og estere deraf til behandling af epiteltumorer - Google Patents

Anvendelse af 9-cis-retinsyre, salte og estere deraf til behandling af epiteltumorer

Info

Publication number
DK0552624T3
DK0552624T3 DK93100257T DK93100257T DK0552624T3 DK 0552624 T3 DK0552624 T3 DK 0552624T3 DK 93100257 T DK93100257 T DK 93100257T DK 93100257 T DK93100257 T DK 93100257T DK 0552624 T3 DK0552624 T3 DK 0552624T3
Authority
DK
Denmark
Prior art keywords
esters
salts
treatment
retinoic acid
cis
Prior art date
Application number
DK93100257T
Other languages
Danish (da)
English (en)
Inventor
Werner Bollag
Joseph Francis Grippo
Arthur Levin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK0552624T3 publication Critical patent/DK0552624T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Fats And Perfumes (AREA)
  • Saccharide Compounds (AREA)
DK93100257T 1992-01-22 1993-01-11 Anvendelse af 9-cis-retinsyre, salte og estere deraf til behandling af epiteltumorer DK0552624T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82378692A 1992-01-22 1992-01-22
US82392892A 1992-01-22 1992-01-22
US82374192A 1992-01-22 1992-01-22
US82464792A 1992-01-23 1992-01-23

Publications (1)

Publication Number Publication Date
DK0552624T3 true DK0552624T3 (da) 2000-09-25

Family

ID=27505866

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93100257T DK0552624T3 (da) 1992-01-22 1993-01-11 Anvendelse af 9-cis-retinsyre, salte og estere deraf til behandling af epiteltumorer

Country Status (20)

Country Link
EP (1) EP0552624B1 (cs)
JP (1) JP3631259B2 (cs)
CN (2) CN1068200C (cs)
AT (1) ATE194077T1 (cs)
AU (1) AU667864B2 (cs)
CA (1) CA2087251C (cs)
CY (1) CY2251B1 (cs)
CZ (1) CZ282548B6 (cs)
DE (1) DE69328910T2 (cs)
DK (1) DK0552624T3 (cs)
ES (1) ES2148184T3 (cs)
GR (1) GR3034323T3 (cs)
HU (2) HU212734B (cs)
IL (1) IL104450A (cs)
NO (1) NO302274B1 (cs)
NZ (1) NZ245686A (cs)
PH (1) PH31621A (cs)
PT (1) PT552624E (cs)
RU (1) RU2119333C1 (cs)
TW (1) TW226329B (cs)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679171B2 (en) 1991-12-18 1997-06-26 Baylor College Of Medicine Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US5968989A (en) 1991-12-18 1999-10-19 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US7056954B2 (en) 1991-12-18 2006-06-06 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5962731A (en) * 1992-04-22 1999-10-05 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5549888A (en) * 1994-01-31 1996-08-27 Procter & Gamble Aqueous topical anti-acne compositions of low pH
US5534261A (en) * 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same
US7115728B1 (en) 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US5821254A (en) * 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
AU5721096A (en) * 1995-04-21 1996-11-07 Ligand Pharmaceuticals Incorporated Inhibition of apoptosis in cells expressing fas-ligand follo wing activation
DE19523079A1 (de) * 1995-06-26 1997-01-02 Basf Ag Ester und Amide der 9(Z)-Retinsäure
DK0859608T3 (da) * 1995-09-18 2004-06-14 Ligand Pharm Inc Behandling af NIDDM med RXR-agonister
CA2204616C (en) 1995-09-18 2002-12-17 Ranjan Mukherjee Ppar gamma antagonists for treating obesity
TW442459B (en) * 1996-04-15 2001-06-23 Hoffmann La Roche Retinoid compounds, pharmaceutical composition comprising same and process for the preparation thereof
FR2765480B1 (fr) 1997-07-07 1999-09-10 Oreal Utilisation pour le revetement des matieres keratiniques d'un materiau polymerique hybride ; compositions cosmetiques ou dermatologiques
AU8588798A (en) 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
AU1707599A (en) * 1998-03-20 1999-10-18 Warner-Lambert Company Retinoid-glitazone combinations
MXPA01010108A (es) 1999-04-07 2002-06-04 Sankyo Co Compuestos de derivados de amina.
AU3082901A (en) * 1999-11-23 2001-06-04 Gerhart Graupner Modulation of signal transduction
RU2214830C2 (ru) * 2001-12-03 2003-10-27 Рязанский государственный медицинский университет им. акад. И.П.Павлова Способ лечения и профилактики местных лучевых реакций на коже
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
RU2197235C1 (ru) * 2002-04-05 2003-01-27 Фармацевтическое научно-производственное предприятие "Ретиноиды" (акционерное общество закрытого типа) Раствор для лечения заболеваний кожи, способ его получения и способ лечения заболеваний кожи
AU2003223477A1 (en) * 2002-04-05 2003-10-27 University Of Utah Research Foundation Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2
AU2003270414A1 (en) * 2002-09-06 2004-03-29 Oregon Health And Science University Effect of vitamin a gel on paranasal sinus mucosal regeneration
EP1527774A1 (en) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
JP4825957B2 (ja) * 2005-03-29 2011-11-30 国立大学法人 鹿児島大学 抗腫瘍剤
AU2009352678B2 (en) 2009-09-15 2015-05-21 Eluminex Biosciences (Suzhou) Limited Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
JP2013527155A (ja) * 2010-04-16 2013-06-27 ダボス ライフ サイエンス ピーティーイー. リミテッド 皮膚科用途のための少なくとも1つのビタミンe成分およびチロシナーゼ阻害剤の相乗的相互作用
BR112012026939A2 (pt) 2010-04-19 2016-07-12 Quadra Logic Tech Inc método para tratamento de um paciente sofrendo da perda ou debilitação da visão
MX389866B (es) 2012-03-01 2025-03-20 Retinagenix LLC El uso de 9-cis-retinil acetato para mejorar la funcion visual de un sujeto que padece de perdida de la funcion visual originada por una deficiencia retinoide endogena de 11-cis retinal.
JP6182728B2 (ja) * 2012-11-02 2017-08-23 国立大学法人名古屋大学 幹細胞を標的とした薬効及び毒性の評価法
US20230320967A1 (en) 2020-09-11 2023-10-12 Chemyunion Ltda. Composition, use of the composition, cosmetic method for modulating the production of sebum
JP2025508115A (ja) * 2022-03-08 2025-03-21 マスタリー バイオテック カンパニー,リミテッド レチノイン酸および炭水化物を含む医薬組成物ならびにその使用
WO2025077810A1 (zh) * 2023-10-12 2025-04-17 南京纽邦生物科技有限公司 预防或延缓皮肤衰老及维持或改善皮肤状况的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA713539B (en) * 1970-06-23 1972-02-23 Hoffmann La Roche Pharmaceutical compositions
CA1326633C (en) * 1987-04-06 1994-02-01 Gerd Plewig Treatment of aged skin with oral 13-cis-retinoic acid
US4994491A (en) * 1988-12-14 1991-02-19 Molecular Design International Dermal uses of trans-retinoids for the treatment of cancer
LU86969A1 (fr) * 1987-08-12 1989-03-08 Oreal Association de derives de pyrimidine et de retinoides en composants separes pour induire et stimuler la croissance des cheveux et diminuer leur chute
AU679171B2 (en) * 1991-12-18 1997-06-26 Baylor College Of Medicine Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor

Also Published As

Publication number Publication date
JPH06107542A (ja) 1994-04-19
CZ372892A3 (en) 1993-12-15
IL104450A (en) 1997-03-18
DE69328910D1 (de) 2000-08-03
EP0552624B1 (en) 2000-06-28
HU9300116D0 (en) 1993-04-28
NO302274B1 (no) 1998-02-16
CY2251B1 (en) 2003-07-04
IL104450A0 (en) 1993-05-13
AU667864B2 (en) 1996-04-18
CN1155376C (zh) 2004-06-30
NO930206L (no) 1993-07-23
PH31621A (en) 1999-01-12
RU2119333C1 (ru) 1998-09-27
CZ282548B6 (cs) 1997-08-13
ATE194077T1 (de) 2000-07-15
HUT63053A (en) 1993-07-28
JP3631259B2 (ja) 2005-03-23
NO930206D0 (no) 1993-01-21
DE69328910T2 (de) 2001-01-11
AU3186193A (en) 1993-07-29
CN1074826A (zh) 1993-08-04
CA2087251A1 (en) 1993-07-23
PT552624E (pt) 2000-10-31
EP0552624A1 (en) 1993-07-28
CN1068200C (zh) 2001-07-11
TW226329B (cs) 1994-07-11
HU211167A9 (en) 1995-11-28
HU212734B (en) 1996-10-28
CA2087251C (en) 2003-06-24
CN1256916A (zh) 2000-06-21
NZ245686A (en) 1995-05-26
ES2148184T3 (es) 2000-10-16
GR3034323T3 (en) 2000-12-29

Similar Documents

Publication Publication Date Title
DK0552624T3 (da) Anvendelse af 9-cis-retinsyre, salte og estere deraf til behandling af epiteltumorer
RU93005355A (ru) Фармакологические композиции
DE3850109D1 (de) 13-trans-retinsäureester.
DK0396184T3 (da) Anvendelse af ketoconazol og et retinoid til behandling af acne vulgaris
EP0303915A3 (en) Retinoids for the treatment of skin damaged by light
EP0213765A3 (en) A method and device for performing transluminal angioplasty
DE602004016847D1 (de) Topische verwendung von valproinsäure zur behandlung von psoriasis und akne
DK0781551T3 (da) Retinoid-formuleringer i porøse mikrosfærer til nedsat irritation og forbedret stabilitet
FR2562539B1 (fr) Nouveaux derives de l'acide vinyl-4 benzoique, leur procede de preparation et leurs applications en therapeutique et comme ligands
RU93047799A (ru) Композиции, содержащие ретиноевые кислоты и токоферол
DK0380367T3 (da) Præparater og fremgangsmåde til sygdomsbehandling
ES2058024A1 (es) Nuevo derivado arilpropionico, procedimiento de fabricacion del mismo y su utilizacion como analgesico.
MC2078A1 (fr) Emploi d'alezastine comme matiere active contre le psoriasis et des maladies inflammatoires
ATE161419T1 (de) Kosmetische zusammensetzung, die einen lipidstoff und eine hydroxy - oder ketofettsäure enthält
KR930016100A (ko) 약제학적 조성물
ATE70183T1 (de) Topische zubereitungen mit gehalt an teer und fettsaeuren.
ATE113209T1 (de) Verwendung von 5-amino-salicylsäure für die behandlung von hautkrankheiten.
TR199900662T2 (xx) 1-Hidroksi-2-piridonlar�n seborik dermatit tedavisi amac�yla kullan�m�
ATE46817T1 (de) Verwendung von 6-(z)- bzw. 2-(z)-konfigurierten 3,7,11-trimethyl-dodeca-2,6,10-trien-1-olen als bakteriostatikum in kosmetischen produkten.
LV10391A (lv) Alkilfosforskabes savienojumu izmantosana psoriazes tipa slimibu arstesanai
Arrieta et al. Honeycomb atrophy on the right cheek
AP2000002004A0 (en) Method of treatment for dermatological disorders and compositions therefor.
ATE97812T1 (de) Therapeutische verwendung des isopropylesterderivates von monosialogangliosiden bei erkrankungen des nervensystems, begleitet von entzuendungen.
RU94016406A (ru) Способ лечения рожистого воспаления
IE811612L (en) Thiazoles